Role of Metabolomics in Age-Related Macular Degeneration

Related

• 

  GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results

  Jeffrey S. Heier, MD

  Arshad M. Khanani, MD, MA, FASRS

  Updates from the Field

  2022

• 

  Expert Panel: Pegcetacoplan Safety

  Andre J. Witkin, MD

  David A. Eichenbaum, MD, FASRS

  Samuel Anthony Minaker, MD, MSc

  Janani Singaravelu, MS, MD

  Sunir J. Garg, MD, FACS, FASRS

  Annual Meeting Talks

  2024

• 

  Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy

  Glenn J. Jaffe, MD

  Annual Meeting Talks

  2022